Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth

Thursday, January 10, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CHAPEL EN LE FRITH, England, January 9 Peakdale MolecularLtd a leading provider in specialist chemistry services to the pharmaceuticalindustry has announced today that they have successfully completed a GBP1mround of equity funding which will enable Peakdale to continue the expansionof its facilities in the UK to support its continued rapid growth.

The investors in this round were led by Solon Ventures LP, advised bySolon Ventures Ltd, and were supported by a number of existing investors.

Commenting on the deal, Peakdale's Commercial Director Ray Fisher said:"I am very grateful for being introduced to the team at Solon Ventures atsuch an important time in Peakdale's history. With our plans for aggressivegrowth, Solon's sector knowledge and desire to actively support suchactivities, together we appear to have the ingredients of a perfect synergy."

Adding to this, Solon Ventures Ltd Managing Director Angus Whiteley said:"We are delighted to be involved with Ray and his team at Peakdale in thisexciting stage of its development. With its excellent reputation and highquality services, we believe Peakdale is very well placed to continue tosupport the pharmaceutical and biotech industries in the future. We lookforward to playing an active role, based on our experience of the sector, inhelping the company achieve its growth and international aspirations."

About Peakdale Molecular

Peakdale Molecular was founded in 1992. Today the Company's customersinclude the majority of the major global pharmaceutical companies and anincreasing number of biotechnology companies. Its teams of chemists combineexperience in pharmaceutical R&D and process development, medicinalchemistry, parallel synthesis and fine chemicals to deliver unique chemistrysolutions to a range of drug discovery challenges.

The application of less commonly used chemistry, including hightemperature/pressure reactions, proprietary heterocyclic chemistry andnucleoside synthesis, enables Peakdale's chemists to generate uniquecompounds for drug discovery. Peakdale operates in several distinct marketsproviding novel screening compounds, targeted screening libraries, catalogueintermediates, custom synthesis and contract research. Further informationabout the Company can be obtained at

About Solon Ventures LPSolon Ventures LP is a Jersey-based limited partnership that invests inprivate UK healthcare and technology companies. The fund is advised by SolonVentures Ltd, a UK company that advises GBP35m of venture capital investmentfor a range of clients. Peakdale Molecular Ray Fisher Commercial Director Peakdale Molecular Ltd Peakdale Science Park Sheffield Road Chapel-en-le-Frith High Peak SK23 0PG UK Tel +44(0)1298-816700 Fax +44(0)1298-816701 Angus Whiteley Managing Director Solon Ventures Ltd 24 Old Bond Street London W1S 4AW UK Tel +44(0)20-7535-4912 Fax +44(0)20-7493-9172

SOURCE Peakdale Molecular

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store